GalNAc Monomer for Liver-Targeted Nucleic Acid Drug Delivery
Summary
The USPTO has published a patent application detailing a GalNAc monomer for liver-targeted delivery of small nucleic acid drugs. The application, filed by inventors Zeao Huang et al., describes a compound that enhances drug efficacy through efficient liver targeting.
What changed
This document is a publication of a US patent application (US20260085320A1) by the USPTO. It describes a novel GalNAc monomer comprising a ribose ring or derivative, intended for the liver-targeted delivery of small nucleic acid drugs. The application highlights that conjugates prepared from this compound can achieve efficient liver targeting and enhance drug efficacy, specifically mentioning a compound of formula (I).
While this is a patent application and not a regulatory rule, it signals potential future developments in drug delivery technology. Companies involved in nucleic acid therapeutics, particularly those targeting liver conditions, should be aware of this innovation. There are no immediate compliance obligations or deadlines associated with this patent application publication, but it may influence future research, development, and intellectual property strategies in the pharmaceutical sector.
Archived snapshot
Mar 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
GALNAC MONOMER COMPRISING RIBOSE RING OR DERIVATIVE STRUCTURE THEREOF AND USE THEREOF IN LIVER-TARGETED DELIVERY OF SMALL NUCLEIC ACID DRUGS
Application US20260085320A1 Kind: A1 Mar 26, 2026
Inventors
Zeao Huang, Gengshen Song, Zhikang Tian, Shuo Yang, Yucheng Wu, Rui Fu
Abstract
The present disclosure provides a GalNAc monomer comprising a ribose ring or a derivative structure thereof and a use thereof in liver-targeted delivery of small nucleic acid drugs. Specifically provided is a compound of formula (I) or a pharmaceutically acceptable salt thereof. The GalNAc-conjugated oligonucleotide prepared from the GalNAc compound provided by the present disclosure can achieve efficient liver-targeted delivery and enhance drug efficacy.
CPC Classifications
C12N 15/1137 A61P 9/12 C12N 15/1131 C12N 2310/11 C12N 2310/14 C12N 2310/315 C12N 2310/351 C12N 2320/32 C12Y 304/21027 C12Y 304/21061
Filing Date
2025-09-22
Application No.
19336466
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.